Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Equity Average (2016 - 2025)

Historic Equity Average for Organogenesis Holdings (ORGO) over the last 10 years, with Q3 2025 value amounting to $244.2 million.

  • Organogenesis Holdings' Equity Average fell 990.28% to $244.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $244.2 million, marking a year-over-year decrease of 990.28%. This contributed to the annual value of $270.8 million for FY2024, which is 50.92% down from last year.
  • As of Q3 2025, Organogenesis Holdings' Equity Average stood at $244.2 million, which was down 990.28% from $238.1 million recorded in Q2 2025.
  • Organogenesis Holdings' Equity Average's 5-year high stood at $278.3 million during Q1 2024, with a 5-year trough of $149.5 million in Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $255.4 million (2022), whereas its average is $243.8 million.
  • As far as peak fluctuations go, Organogenesis Holdings' Equity Average skyrocketed by 34212.51% in 2021, and later plummeted by 1207.45% in 2025.
  • Over the past 5 years, Organogenesis Holdings' Equity Average (Quarter) stood at $215.3 million in 2021, then rose by 21.25% to $261.0 million in 2022, then increased by 6.42% to $277.8 million in 2023, then dropped by 2.54% to $270.7 million in 2024, then fell by 9.8% to $244.2 million in 2025.
  • Its Equity Average stands at $244.2 million for Q3 2025, versus $238.1 million for Q2 2025 and $252.9 million for Q1 2025.